CoChat

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis

Open access
Harms, Maren H, de Veer, Rozanne C, Lammers, Willem J, Corpechot, Christophe, Thorburn, Douglas, Janssen, Harry L A, Lindor, Keith D, Trivedi, Palak J, Hirschfield, Gideon M, Pares, Albert, Floreani, Annarosa, Mayo, Marlyn J, Invernizzi, Pietro, Battezzati, Pier Maria, Nevens, Frederik, Ponsioen, Cyriel Y, Mason, Andrew L, Kowdley, Kris V, Hansen, Bettina E, Buuren, Henk R van, van der Meer, Adriaan J · 2020 · Gut
Cited by 46

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Objective: The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death among patients with PBC. Methods: The NNT was calculated based on the untreated LT-free survival and HR of UDCA with respect to LT or death as derived from inverse probability of treatment weighting-adjusted Cox proportional hazard analyses within the Global PBC Study Group database. Results: We included 3902 patients with a median follow-up of 7.8 (4.1–12.1) years. The overall HR of UDCA was 0.46 (95% CI 0.40 to 0.52) and the 5-year LT-free survival without UDCA was 81% (95% CI 79 to 82). The NNT to prevent one LT or death within 5 years (NNT 5y) was 11 (95% CI 9 to 13). Although the HR of UDCA was similar for patients with and without cirrhosis (0.33 vs 0.31), the NNT 5y was 4 (95% CI 3 to 5) and 20 (95% CI 14 to 34), respectively. Among patients with low alkaline phosphatase (ALP) (≤2× the upper limit of normal (ULN)), intermediate ALP (2–4× ULN) and high ALP (>4× ULN), the NNT 5y to prevent one LT or death was 26 (95% CI 15 to 70), 11 (95% CI 8 to 17) and 5 (95% CI 4 to 8), respectively. Conclusion: The absolute clinical efficacy of UDCA with respect to LT or death varied with baseline prognostic characteristics, but was high throughout. These findings strongly emphasise the incentive to promptly initiate UDCA treatment in all patients with PBC and may improve patient compliance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2019-319057

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 14

  1. Carey, 2015, Primary biliary cirrhosis, The Lancet, 386, 1565, 10.1016/S0140-6736(15)00154-3 · DOI · Paper page
  2. Prince, 2002, Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years, Gastroenterology, 123, 1044, 10.1053/gast.2002.36027 · DOI · Paper page
  3. 2014, Working subgroup for clinical practice guidelines for primary biliary C. guidelines for the management of primary biliary cirrhosis: the intractable hepatobiliary disease Study Group supported by the Ministry of health, labour and welfare of Japan, Hepatol Res, 44, 71, 10.1111/hepr.12270 · DOI
  4. Haboubi, 2019, FRI-057-A review of primary biliary cholangitis practice in Wales: time for specialist care, J Hepatol, 70, e409, 10.1016/S0618-8278(19)30807-2 · doi:10.1016/s0618-8278(19)30807-2
  5. Lu, 2018, Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment, Clin Gastroenterol Hepatol, 16, 1342, 10.1016/j.cgh.2017.12.033 · DOI · Paper page
  6. Robins, 2000, Marginal structural models and causal inference in epidemiology, Epidemiology, 11, 550, 10.1097/00001648-200009000-00011 · DOI · Paper page
  7. Austin, 2014, The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments, Stat Med, 33, 1242, 10.1002/sim.5984 · DOI · Paper page
  8. Heagerty, 2005, Survival model predictive accuracy and ROC curves, Biometrics, 61, 92, 10.1111/j.0006-341X.2005.030814.x · DOI · Paper page
  9. Naylor, 1992, Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?, Ann Intern Med, 117, 916, 10.7326/0003-4819-117-11-916 · DOI · Paper page
  10. Caverly, 2014, Confusing relative risk with absolute risk is associated with more Enthusiastic beliefs about the value of cancer screening, Med Decis Making, 34, 686, 10.1177/0272989X14526641 · DOI
  11. Bucher, 1994, Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration, BMJ, 309, 761, 10.1136/bmj.309.6957.761 · DOI · Paper page
  12. Saffioti F , Gurusamy KS , Eusebi LH , et al . Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;28.doi:10.1002/14651858.CD011648 · DOI · Paper page
  13. Lefkowitch, 2007, Liver biopsy assessment in chronic hepatitis, Arch Med Res, 38, 634, 10.1016/j.arcmed.2006.08.005 · DOI
  14. ter Borg, 2006, Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients, Am J Gastroenterol, 101, 2044, 10.1111/j.1572-0241.2006.00699.x · DOI · Paper page

Cited by

See all 46

Metadata

Authors
Harms, M. H., de Veer, R. C., Lammers, W. J., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Trivedi, P. J., Hirschfield, G. M., Pares, A., Floreani, A., Mayo, M. J., Invernizzi, P., Battezzati, P. M., Nevens, F., Ponsioen, C. Y., Mason, A. L., Kowdley, K. V., Hansen, B. E., Buuren, H. R. V., & van der Meer, A. J.
Venue
Gut
Publisher
BMJ
Published
2019-12-16
Volume
69
Issue
8
Pages
1502-1509
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2995022330
Cited by
46
References
13
FWCI
2.98
Type
journal article
Language
en
Open access
hybrid
Funders
Intercept pharmaceuticals (Unrestricted grant)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. https://app.cochat.ai/papers/10.1136/gutjnl-2019-319057
The paper
Harms, M. H., de Veer, R. C., Lammers, W. J., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Trivedi, P. J., Hirschfield, G. M., Pares, A., Floreani, A., Mayo, M. J., Invernizzi, P., Battezzati, P. M., Nevens, F., Ponsioen, C. Y., Mason, A. L., Kowdley, K. V., Hansen, B. E., . . . van der Meer, A. J. (2020). Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut. https://doi.org/10.1136/gutjnl-2019-319057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.